Molecular epidemiology of quinolone resistance Acinetobacter spp.

Clinical Microbiology and Infection

Volumn 4, Issue 5, 1998, Pages 248-254

  Seward, Rebecca J ^a   Towner, Kevin J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Acinetobacter; Molecular epidemiology; Quinolones; Resistance

Indexed keywords

BACTERIAL DNA; BACTERIAL ENZYME; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; DNA SEQUENCE; NONHUMAN; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA;

ACINETOBACTER; BACTERIA (MICROORGANISMS);

EID: 0031831485     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00052.x     Document Type: Article

References (25)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9: 148-65.
2. Buxton AE, Anderson RL, Werdegard D, Atlas E. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus: epidemiologic characteristics. Am J Med 1978; 65: 507-13.
3. Cefai C, Richards J, Gould FK, McPeake P. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect 1990; 15: 177-82.
4. Bergogne-Bérézin E, Joly-Guillou M-L. Hospital infection with Acinetobacter spp.: an increasing problem. J Hosp Infect 1991; 18(suppl A): 250-3.
5. Joly-Guillou M-L, Bergogne-Bérézin E. In vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp. J Antimicrob Chemother 1993; 32: 1285-8.
6. Fass RJ, Barnishan J, Ayers L. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother 1995; 36: 343-53.
7. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378-424.
8. Tillotson GS, Dorrian I, Blondeau J. Fluoroquinolone resistance: mechanisms and epidemiology. J Med Microbiol 1997; 46: 457-61.
9. Everett MJ, Fang Jin Y, Ricci V, Piddock LJV. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996; 40: 2380-6.
10. Nakamura S, Nakamura M, Kojuna T, Yoshida H. GyrA and gyrB mutations in quinolone resistant strains of Escherichia coli. Antimicrob Agents Chemother 1989; 33: 254-5.
11. Vila J, Ruiz T, Marco F, et al. Association between double mutation in gyrA of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38: 2471-9.
12. Hoshino K, Kitamura A, Morrisey I, Sato K, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994; 38: 2623-7.
13. Kumagai Y, Kayo J-I, Hoshino K, Akasaka T, Sato K, Ikeda H. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother 1996; 40: 710-14
14. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia cali. Antimicrob Agents Chemother 1996; 40: 879-85
15. Hirai K, Aoyama H, Suzue S, Irikera J, Iyobe S, Mitsuhashi S. Isolation and characterisation of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother 1986; 31: 582-6.
16. Yoshimura F, Nikaido H. Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol 1982; 152: 636-42.
17. Goldman JD, White DG, Levy SB. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Antimicrob Agents Chemother 1996; 40: 1266-9.
18. Vila J, Ruiz J, Goñi P, Marcos A, Jiminez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995; 39: 1201-3.
19. Vila J, Ruiz J. Goñi P, Jiminez de Anta T. Quinoloneresistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii J Antimicrob Chemother 1997; 39: 757-62.
20. Ehrenstein B, Bernards AT, Dijkshoorn L, et al. Acinetobacter species identification using tRNA fingerprinting. J Clin Microbiol 1996; 34: 2414-20.
21. Seward RJ, Ehrenstein B, Grundmann HJ, Towner KJ. Direct comparison of two commercially available computer programs for analysing DNA fingerprinting gels. J Med Microbiol 1997; 46: 314-20.
22. Deguchi T, Fakuoka A, Yasuda M, et al. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41: 699-701.
23. Ruiz J, Castro D, Goñi P, Santamaria JA, Borrego JJ, Vila J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. J Med Microbiol 1997; 46: 623-8.
24. Moreau NJ, Houot S, Joly-Guillou M-L, Bergogne-Bérézin E. Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones. J Antimicrob Cheniother 1996; 38: 1079-83.
25. Bauernfeind A, Abele-Horn M, Emmerling P, Jungwirth R. Multiclonal emergence of ciprofloxacin resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother 1994; 34: 1074-6.